MALVERN, Pa., April 27, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that clinical data from its Phase 3 ROMAN trial of avasopasem for severe oral mucositis will be presented in an oral presentation at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7, 2022 in Chicago, Illinois.
Galera to Present at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here